Chinese medicine innovation is booming, these three points should be noted

[pharmaceutical network market analysis] with the acceleration of aging and the high incidence of chronic diseases, huge market demand has put pressure on the innovation and supply of Chinese pharmaceutical market and pharmaceutical enterprises In the past, the strategy of enterprises competing for market scale by low-level generic drugs and auxiliary drugs and exchanging drug rebate for market share is being seriously squeezed At present, it is generally believed that the industry has reached the point where it is difficult to survive without innovation It's worth noting that there is a flourishing trend of pharmaceutical innovation in China (photo source: pharma Com) But for pharmaceutical companies, most of them are just novices in the long-distance competition of pharmaceutical innovation In the future, with the deepening trend of cross-border cooperation and global resource allocation, how to innovate better and avoid failure has become an urgent problem for enterprises Innovation should not be urgent, but should be steady and steady In recent years, in the Chinese market, with a series of approval reforms and the introduction of policies to encourage innovative drugs, a large number of enterprises, including Hengrui pharmaceutical, Kanghong pharmaceutical, Baiji Shenzhou, Fosun Pharmaceutical, etc., are gradually forming "Chinese innovation" in the wave of global pharmaceutical innovation through the continuous research and development of additional drugs But in the case of great innovation forms, we should also see that innovation is not easy and smooth, and not all enterprises can succeed At present, China's medicine is still at the turning point from imitation to innovation After the "fast follow" tide, how to initiate the research and development of new drugs with real clinical and market value, stand out from the homogenization research and development, and accelerate the listing in China and even in the world, is a long-term topic that all pharmaceutical companies and new drug development institutions are facing together and will take time to study Pay attention to the excavation and cultivation of professional talents At present, the global pharmaceutical market is undergoing tremendous changes, especially in 2019 Under the influence of consistency evaluation and "4 + 7" volume procurement and other policies, the rapid flow of talents in the field of innovative drugs in China has gradually become the norm in the industry According to incomplete statistics, in 2019, at least 90 executives resigned, including Novartis, Merck, Mercedes, Taiji group, Li Zhu group, Tianmu pharmaceutical, essence pharmaceutical, etc Although the medical pattern changes, the personnel changes are inevitable However, pharmaceutical enterprises also need to actively adjust and recruit talents structure according to market development trend and their own needs After all, under the background that innovative drugs and high-end generic drugs have become the new research and development direction, more experienced and professional high-level personnel or become the main force of the development of domestic pharmaceutical enterprises In fact, nowadays, not only the pharmaceutical industry is short of talents, but also the pharmaceutical equipment industry is short of talents It is said that some enterprises can not recruit professional talents even if they offer high annual salary Therefore, some enterprises have made great efforts in the recruitment, training, training and training of talent echelons At the same time of improving the training mechanism, we also set up cadre training courses for professional talents, which cost millions of yuan every year There are even enterprises that send technicians to study abroad Deepening cooperation with other institutions to reduce the pressure of research and development At present, the cost of innovative drug research and development is increasingly high, and more and more funds are needed to support research And the faster way to carry out innovative drug research and development is to cooperate with universities or research institutions Universities and research institutions have human, material and knowledge advantages Pharmaceutical enterprises can find them and become good partners In fact, the penetration rate of cro industry in the global pharmaceutical market is in a rapid growth stage, from 18% in 2006 to 44% in 2017 It is expected that the penetration rate of cro industry in the world will reach 54% by 2020 Therefore, outsourcing has gradually become a way for pharmaceutical companies to avoid risks Especially for many small and medium-sized pharmaceutical enterprises with insufficient funds, due to the lack of their own facilities and R & D personnel, it is a more sensible approach to choose to complete clinical development with the help of pharmaceutical R & D and production service companies Conclusion: as a whole, China is still a new player in the long-distance race of pharmaceutical innovation On this road of innovation, we need to guard against arrogance and impetuosity, not only pay attention to the beautiful scenery around, but also take every step steadily.